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Chagas disease as a mechanistic model 
for testing a novel hypothesis
A doença de Chagas como um modelo mecanicista 
para testar uma nova hipótese
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ABSTRACT
The association between depression and cardiovascular disease is well documented. Nevertheless, the process through which they are linked remains 
unknown, as does the direction of this relationship. Studies have suggested both that depression is a risk factor for heart disease and that heart disease 
is a risk factor for depression. A number of studies have established that a relationship exists between depression and inflammation, with alterations in 
the levels of inflammatory markers (IL-1, IL-6, TNF-alpha and others). Depressive symptoms have also been identified in many diseases characterized 
by inflammatory processes e.g. rheumatoid arthritis, bronchial asthma, diabetes, tuberculosis and cardiovascular diseases. In this brief viewpoint, we 
explain and propose how to use Chagas disease, a disorder characterized by inflammatory processes and leading to cardiovascular and autonomic 
problems, as a model for studying the directionality of the relationship between heart disease and depression.
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RESUMO
A associação entre depressão e doença cardiovascular está bem documentada. Não obstante, o processo pelo qual está associada permanece 
desconhecido, assim como o sentido desta associação. Estudos têm sugerido que tanto a depressão é um fator de risco para a doença cardiovascular 
quanto esta o é para a depressão. Uma série de trabalhos tem estabelecido que uma relação existe entre depressão e inflamação, com alterações 
evidenciadas por marcadores de inflamação (IL-1, IL-6, TNF alfa e outros). Sintomas de depressão também têm sido identificados em diversas 
doenças caracterizadas por processos inflamatórios, tais como artrite reumatoide, asma brônquica, diabete, tuberculose e doenças cardiovasculares. 
Nesta breve opinião é explicitado e proposto como empregar a doença de Chagas, um agravo caracterizado por processos inflamatórios e indutor de 
problemas cardiovasculares e autonômicos, como um modelo de estudo da direcionalidade da relação entre doença cardíaca e depressão.
Palavras-chaves: Doença de Chagas. Depressão.
The association between depression and cardiovascular 
disease is well documented13. Cross-sectional and prospective 
analyses have shown that a prior history of depression is associated 
with an increased risk of developing heart disease, and of 
increased morbidity among those that do.
Research1 has also suggested that heart disease may precede 
the onset of depression8 9. However, the processes through 
which depression and cardiovascular disease are linked remain 
unknown.
A number of studies have established that a relationship 
exists between depression and inflammation24. Various studies on 
depression have found alterations in the levels of inflammatory 
markers (IL-1, IL-6, tumor necrosis factor [TNF-D]20 29 and 
others). Depressive symptoms have also been identified in many 
diseases characterized by inflammatory processes, e.g. rheumatoid 
arthritis18  30, asthma27, diabetes19, tuberculosis1 and cardiovascular 
disease31 35.
The direction of this relationship remains unclear. Studies 
have suggested both that depression is a risk factor for heart 
disease and that heart disease puts people at risk of depression. 
The robust comorbidity between the two conditions has led us to 
propose a third mechanism: that depression and cardiovascular 
disease are outcomes from the same process, and thus that there 
is no directionality to the relationship. To this end, we propose 
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to use Chagas disease, a disorder characterized by inflammatory 
processes and leading to cardiovascular outcomes, as a model for 
studying the relationship between heart disease and depression. 
WHY CHAGAS DISEASE?
Chagas disease presents complex disease progression that can 
be broken down, for most patients, into acute, indeterminate and 
chronic stages. Once the individual has survived the acute phase, 
the disease may be asymptomatic and may go undetected for many 
years. During this indeterminate stage, the disease is not inactive, 
but gradually develops via the cardiovascular system, where it 
produces microvascular changes, cardiac muscle remodeling and 
cardiac dysautonomia23. In the chronic stage, the clinical outcomes 
are sudden death, complex arrhythmia, ventricular aneurysms, 
heart failure, thromboembolism and stroke23.
The pathology of Chagas disease can be almost completely 
explained as a systemic parasitic stressor initiating a cascade of 
immunological processes. Our model shows how these processes 
account for Chagas pathology and, when applied to the body 
as a whole, how they would also provoke changes in the brain 
consistent with neurocognitive dysfunction and depression. In 
this paper, we propose using Chagas disease as a model for 
neurocognitive/mood changes in relation to inflammation, which, 
if our theory is correct, we predict should be present.
A PROPOSED MECHANISM
Immune system stimulation can be triggered by many types 
of stressors, including parasitic stressors, as in Chagas disease. 
When there is stress, the body recognizes, evaluates and adapts 
to the adverse events by initiating a cascade of events meant both 
to eradicate the stressor and to return the body to homeostatic 
balance. When the stress becomes chronic, the persistence of 
these processes becomes maladaptive and, as has been proposed, 
initiates a series of established biological events that lead to 
outcomes in the neurocognitive and cardiovascular spheres. 
Macrophages, the first phase of the inflammatory response, 
trigger the release of cytokines, which are hormone-like messengers 
that initiate other changes in the body. In the liver, acute phase 
reactants (APRs), which include fibrinogen and prothrombin, are 
produced11. When converted, respectively, to fibrin and thrombin 
forms, they provide a meshwork for thrombus formation2. Adhesion 
molecules, which are normally stimulated to resolve an acute 
condition through attracting white blood cells, are produced 
in excess, resulting in increased adhesiveness of the vascular 
wall, and promoting the accumulation of a pathological number 
of macrophages and lymphocytes3 12. Cytokines also increase 
the concentration of various lipids such as triglycerides, 
cholesterol and free fatty acids10. Increases in intracellular 
calcium in conjunction with platelet agonists like thromboxane 
A2 cause further platelet aggregation5 15. In situations of chronic 
inflammation, all these factors lead to atherosclerosis and vascular 
remodeling.
Within cells, cytokines stimulate the activity of cyclooxygenase, 
thereby leading to synthesis of thromboxane A2 (TXA2), 
prostacyclin (PGI2), and prostaglandins (PGE2).  Prostaglandins 
are potential inducers of intracellular oxidative stress – composed 
of nitric oxide and free radicals – which leads to cell degeneration 
and death14. Oxidative stress inhibits mitochondrial function in 
cells throughout the brain and the body17. Additionally, in neuronal 
populations, cytokines and glucocorticoids in conjunction with 
neopterin (an APR) can alter the metabolism of tryptophan from 
normal production of 5HTP (serotonin) to the kynurenine pathway 
and the synthesis of quinolinic acid21. Increased production 
of this NMDA agonist, coupled with increased calcium in the 
presence of arginine, escalates nitric oxide synthesis and causes 
neuron damage from oxidative stress, thus leading to apoptosis 
in neuronal, astrocytic, and microglial cells7 16.
When cellular damage by oxidative stress and apoptosis damages 
or kills serotonergic neurons, the subsequent decrease in serotonin can 
have further effects on the vasculature. Lower levels of plasma-bound 
5HT induce platelet receptor upregulation, which in turn increases 
platelet reactivity and the aggregation response6 34. Lower levels of 
5HT may also promote HPA axis hyperactivity, thereby increasing 
glucocorticoid levels and reducing the sensitivity to the feedback 
loop that is intended to return the body to homeostasis32. In turn, 
corticosteroids can activate the sympathetic nervous system, 
thus increasing heart rate and blood pressure and putting more 
pressure on the cardiovascular system.
In summary, the total effect of the stressor is the cumulative result 
of a series of biochemical events that result in immune, neurohumoral 
and cardiovascular system dysfunction, as well as changes in the brain. 
Especially because the latter changes affect serotonergic neurons, they 
may manifest as neurocognitive dysfunction and depression. These 
biochemical events are all linked together in a self-perpetuating 
cycle of interlinked systems with positive feedback, with expression 
in the brain and heart and with a parasitic stressor as the initiator. 
The full execution of the pathways described above would hinge 
on an individual’s susceptibility to pathological processes, which is 
associated with his genetic endowment and/or to prenatal/perinatal 
environmental exposure such as low birth weight or hypoxia4 28.
Depression would be consequent to these brain changes. If correct, 
this model explains the perceived directionality of causation on 
which the first two paradigms are founded, and resolves the apparent 
contradiction that they pose.
IMPLICATIONS AND CONCLUSION
Chagas disease pathology is accompanied by many of the 
inflammation-induced changes described above. Microvascular 
changes are extensive in Chagas disease. Increases in blood-born 
oxidative stress markers as well as mitochondrial dysfunction 
caused by oxidative stress are both associated with the progression 
of Chagas disease25 35. Increases in oxidative stress markers have 
also been associated with neuron degeneration and development 
of dysautonomia in other diseases33.
Chagas disease provides a unique model to test our hypothesis. 
The initiator of the inflammatory process is known and well 
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defined, and not dependent on lifestyle choices such as diet, 
smoking, etc. Additionally, the various stages of this disease 
- acute, indeterminate and chronic - make it ideal for studying 
its covariance with neurocognitive and depressive symptoms. A 
search through previous literature yielded only one related study: 
Mangone et al in 1994 suggested that Chagas patients may be impaired 
in their orientation, attention, nonverbal reasoning, information 
processing, learning and sequencing22. Additionally, according to 
Oliveira Jr26, the frequent occurrence of progressive and often 
severe cardiopathy in Chagas patients contributes by augmenting 
any preexisting depression.
A study of this magnitude on a disorder that has not been 
given its due international medical attention will do much to bring 
recognition to this disease, which human migration is spreading 
beyond its typical geographic boundaries.
Demonstration of a common biological mechanism for 
depression and heart disease will provide further opportunities 
for both preventative and ameliorative treatment of both 
conditions. Additionally, by addressing the psychological impact 
of disease, doctors can increase the chances of recovery, insofar 
as depression and neurocognitive dysfunction are associated with 
noncompliance with drug treatment. 
This hypothesis has the potential to significantly alter the way 
we think about depression. Depression is currently treated as an 
illness rather than a symptom of an underlying biological process. 
If inflammation can be identified as a cause of depression, it will 
improve diagnosis and treatment as well as provide insights into 
other diseases in which depression is a symptom.
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